 Michael McDermott
Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperthyroidism | 5 | 2020 | 26 | 1.880 |
Why?
| | Hypothyroidism | 5 | 2020 | 68 | 1.780 |
Why?
| | Graves Disease | 2 | 2020 | 32 | 0.820 |
Why?
| | Osteoporosis | 5 | 2009 | 229 | 0.800 |
Why?
| | Triiodothyronine | 3 | 2020 | 43 | 0.790 |
Why?
| | Thyroid Neoplasms | 2 | 2020 | 278 | 0.770 |
Why?
| | Thyroxine | 3 | 2020 | 63 | 0.700 |
Why?
| | Bone Density Conservation Agents | 2 | 2009 | 61 | 0.630 |
Why?
| | Thyroid Diseases | 4 | 2005 | 30 | 0.620 |
Why?
| | Thyrotoxicosis | 2 | 2020 | 7 | 0.590 |
Why?
| | Hypoglycemic Agents | 2 | 2016 | 1032 | 0.590 |
Why?
| | Vitamins | 2 | 2008 | 158 | 0.570 |
Why?
| | Antithyroid Agents | 4 | 2020 | 11 | 0.550 |
Why?
| | Vitamin D | 3 | 2008 | 354 | 0.550 |
Why?
| | Iodine Radioisotopes | 4 | 2020 | 130 | 0.530 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2012 | 44 | 0.420 |
Why?
| | Thyrotropin | 4 | 2020 | 105 | 0.410 |
Why?
| | Vitamin D Deficiency | 3 | 2009 | 162 | 0.400 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2016 | 2174 | 0.390 |
Why?
| | Diagnosis, Differential | 4 | 2020 | 1384 | 0.380 |
Why?
| | Premenopause | 1 | 2009 | 108 | 0.330 |
Why?
| | Patient Education as Topic | 2 | 2015 | 699 | 0.320 |
Why?
| | Thyroidectomy | 2 | 2020 | 54 | 0.290 |
Why?
| | Endocrinology | 2 | 2004 | 68 | 0.280 |
Why?
| | Thyroid Hormones | 2 | 2020 | 55 | 0.280 |
Why?
| | Pharmacists | 1 | 2008 | 238 | 0.270 |
Why?
| | Hormone Replacement Therapy | 2 | 2020 | 80 | 0.260 |
Why?
| | Bone Density | 4 | 2009 | 449 | 0.260 |
Why?
| | Cardiovascular Diseases | 1 | 2016 | 1798 | 0.250 |
Why?
| | Hospitalization | 2 | 2020 | 1785 | 0.250 |
Why?
| | Reproductive Medicine | 1 | 2004 | 13 | 0.240 |
Why?
| | Professional Practice | 1 | 2003 | 62 | 0.230 |
Why?
| | Humans | 28 | 2020 | 118974 | 0.230 |
Why?
| | Thyrotropin, beta Subunit | 1 | 2002 | 5 | 0.230 |
Why?
| | Blood Glucose | 2 | 2016 | 1939 | 0.220 |
Why?
| | Drug Therapy, Combination | 2 | 2020 | 965 | 0.210 |
Why?
| | Insulin | 2 | 2016 | 2162 | 0.210 |
Why?
| | Diabetes Mellitus | 2 | 2008 | 942 | 0.210 |
Why?
| | Point Mutation | 1 | 2002 | 228 | 0.210 |
Why?
| | Hip Fractures | 1 | 2003 | 79 | 0.210 |
Why?
| | Thyroid Gland | 1 | 2002 | 84 | 0.200 |
Why?
| | Methimazole | 1 | 2020 | 6 | 0.200 |
Why?
| | Myxedema | 1 | 2020 | 1 | 0.190 |
Why?
| | Absorptiometry, Photon | 3 | 2009 | 229 | 0.180 |
Why?
| | Treatment Failure | 1 | 2020 | 341 | 0.180 |
Why?
| | Mass Screening | 3 | 2020 | 1052 | 0.170 |
Why?
| | Diet | 1 | 2007 | 1153 | 0.170 |
Why?
| | Risk Factors | 5 | 2020 | 9000 | 0.170 |
Why?
| | Reference Values | 1 | 2020 | 774 | 0.170 |
Why?
| | Triiodothyronine, Reverse | 1 | 2018 | 2 | 0.170 |
Why?
| | Thyroid Function Tests | 1 | 2018 | 11 | 0.170 |
Why?
| | Physical Examination | 1 | 2020 | 243 | 0.170 |
Why?
| | Female | 16 | 2020 | 61565 | 0.170 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1440 | 0.160 |
Why?
| | Practice Patterns, Physicians' | 2 | 2006 | 1200 | 0.160 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2020 | 301 | 0.160 |
Why?
| | Hypoglycemia | 2 | 2016 | 400 | 0.150 |
Why?
| | Parathyroid Hormone | 2 | 2008 | 99 | 0.150 |
Why?
| | Biomarkers | 2 | 2020 | 3588 | 0.140 |
Why?
| | Insulin Antibodies | 1 | 2016 | 101 | 0.130 |
Why?
| | Pregnancy Complications | 1 | 2020 | 448 | 0.130 |
Why?
| | Referral and Consultation | 1 | 2020 | 648 | 0.130 |
Why?
| | Rituximab | 1 | 2016 | 155 | 0.130 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 900 | 0.130 |
Why?
| | Ambulatory Care | 2 | 2008 | 482 | 0.120 |
Why?
| | Immunologic Factors | 1 | 2016 | 225 | 0.120 |
Why?
| | Aged | 9 | 2016 | 19657 | 0.120 |
Why?
| | Pregnancy | 3 | 2020 | 5691 | 0.110 |
Why?
| | Case-Control Studies | 1 | 2020 | 3171 | 0.110 |
Why?
| | Diabetes Complications | 1 | 2015 | 218 | 0.110 |
Why?
| | Sex Factors | 2 | 2012 | 1781 | 0.110 |
Why?
| | Thyroid Crisis | 1 | 2012 | 7 | 0.110 |
Why?
| | Autoimmune Diseases | 1 | 2016 | 398 | 0.110 |
Why?
| | Age Factors | 2 | 2012 | 2995 | 0.110 |
Why?
| | Aged, 80 and over | 3 | 2008 | 6561 | 0.110 |
Why?
| | Postpartum Thyroiditis | 1 | 2011 | 1 | 0.100 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 522 | 0.100 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2015 | 280 | 0.100 |
Why?
| | Retrospective Studies | 3 | 2020 | 12978 | 0.100 |
Why?
| | Drug Interactions | 1 | 2012 | 352 | 0.100 |
Why?
| | Liver Diseases | 1 | 2012 | 282 | 0.090 |
Why?
| | Risk | 1 | 2012 | 853 | 0.090 |
Why?
| | Adipokines | 1 | 2009 | 46 | 0.090 |
Why?
| | Colorado | 4 | 2009 | 4196 | 0.090 |
Why?
| | Male | 10 | 2016 | 57801 | 0.080 |
Why?
| | Community-Institutional Relations | 1 | 2009 | 91 | 0.080 |
Why?
| | Obesity | 2 | 2015 | 2746 | 0.080 |
Why?
| | Raloxifene Hydrochloride | 1 | 2008 | 13 | 0.080 |
Why?
| | Patient Care | 1 | 2008 | 105 | 0.080 |
Why?
| | Self Administration | 1 | 2008 | 125 | 0.080 |
Why?
| | Kidney Diseases | 1 | 2012 | 439 | 0.080 |
Why?
| | Diphosphonates | 1 | 2008 | 50 | 0.080 |
Why?
| | Pharmaceutical Services | 1 | 2008 | 79 | 0.080 |
Why?
| | Pilot Projects | 2 | 2009 | 1419 | 0.080 |
Why?
| | Professional Role | 1 | 2008 | 153 | 0.070 |
Why?
| | Women's Health | 1 | 2009 | 274 | 0.070 |
Why?
| | Nutrition Policy | 1 | 2007 | 58 | 0.070 |
Why?
| | Insulin Lispro | 1 | 2006 | 35 | 0.070 |
Why?
| | Life Style | 1 | 2009 | 430 | 0.070 |
Why?
| | Phosphorus | 1 | 2007 | 84 | 0.070 |
Why?
| | Nonprescription Drugs | 1 | 2007 | 67 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1185 | 0.070 |
Why?
| | Serum Albumin | 1 | 2007 | 146 | 0.070 |
Why?
| | Body Composition | 1 | 2009 | 653 | 0.070 |
Why?
| | Creatinine | 1 | 2007 | 491 | 0.060 |
Why?
| | Quality of Health Care | 1 | 2009 | 586 | 0.060 |
Why?
| | Patient Compliance | 1 | 2008 | 537 | 0.060 |
Why?
| | Middle Aged | 6 | 2015 | 27617 | 0.060 |
Why?
| | Outpatients | 1 | 2007 | 325 | 0.060 |
Why?
| | Fractures, Bone | 1 | 2009 | 380 | 0.060 |
Why?
| | Thyroid Nodule | 1 | 2003 | 38 | 0.060 |
Why?
| | Densitometry | 1 | 2003 | 30 | 0.060 |
Why?
| | Inpatients | 1 | 2006 | 388 | 0.060 |
Why?
| | Hospitals, University | 1 | 2003 | 172 | 0.050 |
Why?
| | Health Services for the Aged | 1 | 2003 | 71 | 0.050 |
Why?
| | Medical Records | 1 | 2003 | 163 | 0.050 |
Why?
| | Exons | 1 | 2002 | 307 | 0.050 |
Why?
| | Biopsy, Needle | 1 | 2002 | 190 | 0.050 |
Why?
| | Calcium | 1 | 2007 | 1169 | 0.050 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 1137 | 0.050 |
Why?
| | Prevalence | 1 | 2007 | 2326 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2009 | 4552 | 0.050 |
Why?
| | Adenoma | 1 | 2002 | 191 | 0.050 |
Why?
| | Follow-Up Studies | 1 | 2008 | 4596 | 0.040 |
Why?
| | Base Sequence | 1 | 2002 | 2159 | 0.040 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 2071 | 0.040 |
Why?
| | Exercise | 1 | 2009 | 1657 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2015 | 4708 | 0.040 |
Why?
| | Molecular Sequence Data | 1 | 2002 | 2871 | 0.040 |
Why?
| | Risk Assessment | 1 | 2006 | 3057 | 0.040 |
Why?
| | Patient Discharge | 1 | 2003 | 796 | 0.040 |
Why?
| | Biomarkers, Tumor | 1 | 2002 | 1059 | 0.030 |
Why?
| | Prospective Studies | 1 | 2007 | 6471 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2016 | 534 | 0.030 |
Why?
| | Adult | 3 | 2015 | 31512 | 0.020 |
Why?
| | Resistin | 1 | 2009 | 13 | 0.020 |
Why?
| | Biological Factors | 1 | 2009 | 41 | 0.020 |
Why?
| | Severity of Illness Index | 2 | 2009 | 2674 | 0.020 |
Why?
| | Medical Audit | 1 | 2008 | 75 | 0.020 |
Why?
| | Hip Joint | 1 | 2009 | 144 | 0.020 |
Why?
| | Leptin | 1 | 2009 | 231 | 0.020 |
Why?
| | Adiponectin | 1 | 2009 | 226 | 0.020 |
Why?
| | Lumbar Vertebrae | 1 | 2009 | 215 | 0.020 |
Why?
| | Body Mass Index | 1 | 2015 | 2092 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2015 | 1180 | 0.020 |
Why?
| | Program Evaluation | 1 | 2008 | 845 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2009 | 1171 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2016 | 9342 | 0.010 |
Why?
| | Lung | 1 | 2009 | 3664 | 0.010 |
Why?
|
|
McDermott's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|